BRPI0911656A2 - formulações de nanopartículas e usos das mesmas - Google Patents

formulações de nanopartículas e usos das mesmas

Info

Publication number
BRPI0911656A2
BRPI0911656A2 BRPI0911656A BRPI0911656A BRPI0911656A2 BR PI0911656 A2 BRPI0911656 A2 BR PI0911656A2 BR PI0911656 A BRPI0911656 A BR PI0911656A BR PI0911656 A BRPI0911656 A BR PI0911656A BR PI0911656 A2 BRPI0911656 A2 BR PI0911656A2
Authority
BR
Brazil
Prior art keywords
nanoparticle formulations
nanoparticle
formulations
Prior art date
Application number
BRPI0911656A
Other languages
English (en)
Inventor
Chunlin Tao
Neil P Desai
Sherry Xiaopei Ci
Tapas De
Voung Trieu
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of BRPI0911656A2 publication Critical patent/BRPI0911656A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
BRPI0911656A 2008-04-10 2009-04-10 formulações de nanopartículas e usos das mesmas BRPI0911656A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4400608P 2008-04-10 2008-04-10
US9666408P 2008-09-12 2008-09-12
PCT/US2009/040281 WO2009126938A1 (en) 2008-04-10 2009-04-10 Nanoparticle formulations and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0911656A2 true BRPI0911656A2 (pt) 2015-10-13

Family

ID=40785313

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911656A BRPI0911656A2 (pt) 2008-04-10 2009-04-10 formulações de nanopartículas e usos das mesmas

Country Status (11)

Country Link
US (3) US20090263483A1 (pt)
EP (1) EP2288340B1 (pt)
CN (1) CN102056596B (pt)
AU (1) AU2009234127B2 (pt)
BR (1) BRPI0911656A2 (pt)
CA (1) CA2721153C (pt)
ES (1) ES2812529T3 (pt)
IL (1) IL208591A0 (pt)
MX (1) MX2010011165A (pt)
WO (2) WO2009126401A1 (pt)
ZA (1) ZA201008045B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US8137684B2 (en) * 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUE040046T2 (hu) 2002-12-09 2019-02-28 Abraxis Bioscience Llc Gyógyszerészeti készítmények és hatóanyagok beadására szolgáló eljárások
EP1853250B1 (en) 2005-02-18 2011-11-02 Abraxis BioScience, LLC Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
NZ566705A (en) 2005-08-31 2011-06-30 Abraxis Bioscience Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
ZA200802765B (en) 2005-08-31 2009-08-26 Abraxis Bioscience Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
ES2700074T3 (es) 2006-12-14 2019-02-13 Abraxis Bioscience Llc Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano
KR102154459B1 (ko) * 2007-03-07 2020-09-09 아브락시스 바이오사이언스, 엘엘씨 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
EP3326630A3 (en) * 2007-05-03 2018-08-29 Abraxis BioScience, LLC Methods and compositions for treating pulmonary hypertension
DK2155188T3 (da) * 2007-06-01 2013-11-04 Abraxis Bioscience Llc Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
BRPI1012525A2 (pt) 2009-04-15 2018-07-10 Abraxis Bioscience, Llc. composições de nanopatículas isentas de príons e métodos para sua fabricação
AU2011210352A1 (en) 2010-01-26 2012-08-09 Radikal Therapeutics Inc. Compositions and methods for prevention and treatment of pulmonary hypertension
KR101786142B1 (ko) 2010-03-26 2017-10-17 아브락시스 바이오사이언스, 엘엘씨 간세포 암종의 치료 방법
JP6242213B2 (ja) 2010-03-29 2017-12-06 アブラクシス バイオサイエンス， エルエルシー 薬物送達および治療用薬剤の有効性を向上させる方法
KR20130028728A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 암의 치료 방법
KR20180049180A (ko) 2010-06-04 2018-05-10 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
RU2577278C2 (ru) 2010-06-07 2016-03-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы комбинированной терапии для лечения пролиферативных заболеваний
CN109172809A (zh) 2011-04-28 2019-01-11 阿布拉科斯生物科学有限公司 纳米颗粒组合物的血管内递送及其应用
AU2012325801B2 (en) * 2011-10-19 2016-05-12 Mercator Medsystems, Inc. Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation
CN102408397B (zh) * 2011-10-19 2014-08-20 上海贝美医药科技有限公司 紫杉烷类衍生物及其制备方法
JP6162709B2 (ja) 2011-11-01 2017-07-12 セルジーン コーポレイション シチジンアナログの経口製剤を使用して癌を治療する方法
WO2013085902A1 (en) 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
SI2790675T1 (sl) 2011-12-14 2019-11-29 Abraxis Bioscience Llc Uporaba polimernih pomožnih snovi za liofilizacijo ali zamrzovanje delcev
US9913822B2 (en) 2012-04-04 2018-03-13 Halozyme, Inc. Combination therapy with an anti-hyaluronan agent and therapeutic agent
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
NZ630392A (en) 2013-03-12 2016-10-28 Abraxis Bioscience Llc Methods of treating lung cancer
MX2015011753A (es) 2013-03-14 2015-12-07 Abraxis Bioscience Llc Metodos para tratar cancer de vegija.
RS60093B1 (sr) * 2013-09-16 2020-05-29 Astrazeneca Ab Terapeutske polimerne nanočestice i postupci njihove pripreme i primene
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
SI3313401T1 (sl) 2015-06-29 2022-04-29 Abraxis Bioscience, Llc Nanodelci, ki vsebujejo sirolim in albumin, za uporabo pri zdravljenju tumorjev epiteloidnih celic
MY193776A (en) * 2015-09-22 2022-10-27 Univ California Modified cytotoxins and their therapeutics use
US11531030B2 (en) 2017-04-21 2022-12-20 Mayo Foundation For Medical Education And Research Polypeptide-antibody complexes and uses thereof
CA3069004A1 (en) * 2017-07-07 2019-01-10 Epicentrx, Inc. Compositions for parenteral administration of therapeutic agents
EP3661513A4 (en) 2017-07-31 2021-07-14 January Therapeutics, Inc. ORGANOPHOSPHATE DERIVATIVES
RU2020118594A (ru) 2017-11-06 2021-12-09 Рапт Терапьютикс, Инк. Противораковые агенты
CN109813892A (zh) * 2017-11-18 2019-05-28 丹阳亿太生物科技发展有限公司 盐酸赛庚啶快速时间分辨荧光免疫层析定量检测试纸条
RU2020134124A (ru) 2018-03-20 2022-04-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
CN110862410A (zh) * 2018-08-27 2020-03-06 深圳福山生物科技有限公司 三氟甲基硒化合物及其用途
US11708637B2 (en) 2019-08-13 2023-07-25 The Regents Of The University Of California Methods of supporting a graphene sheet disposed on a frame support
CN112569240A (zh) * 2019-09-29 2021-03-30 四川大学华西医院 盐酸氯丙嗪在制备细胞周期素蛋白抑制剂中的用途
CA3158764A1 (en) 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
CN1245156C (zh) * 1993-02-22 2006-03-15 美国生物科学有限公司 用于体内传送生物制品的方法及用于该方法的组合物
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20070117862A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5997904A (en) * 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6528067B1 (en) * 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5536263A (en) * 1994-03-30 1996-07-16 Lectec Corporation Non-occulusive adhesive patch for applying medication to the skin
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
JP4192208B2 (ja) * 1995-09-12 2008-12-10 セファロン リミテッド 加水分解促進性のタキサン疎水性誘導体
US6107332A (en) * 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
US6537539B2 (en) * 1996-01-11 2003-03-25 Human Genome Sciences, Inc. Immune cell cytokine
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US8137684B2 (en) * 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
CN100462066C (zh) * 1997-06-27 2009-02-18 美国生物科学有限公司 药剂的新制剂及其制备和应用方法
CA2369740A1 (en) * 1999-04-22 2000-11-02 American Biosciences, Inc. Long term administration of pharmacologically active agents
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
EP1165068B1 (en) * 2000-02-02 2007-12-19 Florida State University Research Foundation, Inc. C10 heterosubstituted acetate taxanes as antitumor agents
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
HUE040046T2 (hu) * 2002-12-09 2019-02-28 Abraxis Bioscience Llc Gyógyszerészeti készítmények és hatóanyagok beadására szolgáló eljárások
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US8420603B2 (en) * 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
BRPI0515418A (pt) * 2004-08-16 2008-07-22 Nature Technology Corp método para a produção de dna de plasmìdio super-enrolado fechado covalentemente e composição de matéria
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
CA2598510C (en) * 2005-02-18 2011-12-20 Abraxis Bioscience, Inc. Q3 sparc deletion mutant and uses thereof
EP1853250B1 (en) * 2005-02-18 2011-11-02 Abraxis BioScience, LLC Combinations and modes of administration of therapeutic agents and combination therapy
EP1861070B1 (en) * 2005-02-18 2018-01-17 Abraxis BioScience, LLC Drugs with improved hydrophobicity for incorporation in medical devices
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CN101160118A (zh) * 2005-02-24 2008-04-09 依兰药物国际有限公司 多西紫杉醇或其类似物的纳米微粒制剂
NZ566705A (en) * 2005-08-31 2011-06-30 Abraxis Bioscience Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
ZA200802765B (en) * 2005-08-31 2009-08-26 Abraxis Bioscience Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20100112077A1 (en) * 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
ES2700074T3 (es) * 2006-12-14 2019-02-13 Abraxis Bioscience Llc Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano
KR102154459B1 (ko) * 2007-03-07 2020-09-09 아브락시스 바이오사이언스, 엘엘씨 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
EP3326630A3 (en) * 2007-05-03 2018-08-29 Abraxis BioScience, LLC Methods and compositions for treating pulmonary hypertension
DK2155188T3 (da) * 2007-06-01 2013-11-04 Abraxis Bioscience Llc Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
BRPI1012525A2 (pt) * 2009-04-15 2018-07-10 Abraxis Bioscience, Llc. composições de nanopatículas isentas de príons e métodos para sua fabricação

Also Published As

Publication number Publication date
US20180289620A1 (en) 2018-10-11
US20140302157A1 (en) 2014-10-09
AU2009234127A1 (en) 2009-10-15
WO2009126401A1 (en) 2009-10-15
IL208591A0 (en) 2010-12-30
MX2010011165A (es) 2011-02-22
CA2721153A1 (en) 2009-10-15
ZA201008045B (en) 2012-03-28
CN102056596A (zh) 2011-05-11
CA2721153C (en) 2018-10-02
AU2009234127B2 (en) 2015-04-30
CN102056596B (zh) 2015-05-20
WO2009126938A1 (en) 2009-10-15
ES2812529T3 (es) 2021-03-17
US20090263483A1 (en) 2009-10-22
EP2288340B1 (en) 2020-06-24
EP2288340A1 (en) 2011-03-02

Similar Documents

Publication Publication Date Title
BRPI0911656A2 (pt) formulações de nanopartículas e usos das mesmas
BRPI1014160A2 (pt) Formulações de nanopartículas e aplicações das mesmas
BRPI1008709A2 (pt) composições e usos das mesmas.
BRPI0913574A2 (pt) composição de tratamento de acne compreendendo nanoprata e usos
BRPI0912213A2 (pt) preparação cosmética
BRPI0822655A2 (pt) Implemento e sistema para cuidado oral
BRPI1011404A2 (pt) mutantes e usos dos mesmos
BRPI0913447A2 (pt) composição de éster, e, composição para cuidado pessoal.
BRPI0719732A2 (pt) nanopartículas de peptídeo e usos para as mesmas
BRPI0910874A2 (pt) composições e métodos para cuidado da pele
ATE544443T1 (de) Haarpflegezusammensetzung
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BR112013007499A2 (pt) piridazinonas - métodos de criação e usos
BRPI0822817A2 (pt) Implemento para cuidado oral
BRPI0822833A2 (pt) Implemento para cuidado oral
BRPI0922531A2 (pt) composições de cuidado doméstico e pessoal
BRPI1009372A2 (pt) compostos, composição farmacêutica e respectivos usos
BRPI0922691A2 (pt) conjugados de leptina e análogo de leptina e usos dos mesmos
BRPI0917205A2 (pt) vacina polivalente
BR112012003844A2 (pt) vacinas de pttv e diagnóstico
BRPI1015941A2 (pt) formulações de comprimido de 3-cianoquinolina e uso das mesmas.
DE602008002077D1 (de) Hautpflegevorrichtung
BRPI0921947A2 (pt) formulações de proteína terapêutica
BR112012025270A2 (pt) "composição de cuidados pessoais"
BRPI1013647A2 (pt) composições poliméricas degradáveis e usos das mesmas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.